Report overview

The report states that Group revenues increased 52% to £7.78m and operating profit reached £1.73m in 2022. The company also invested in its workforce and instruments, including six hires and the development of Single Cell Proteomics capabilities. TMT/TMTpro-related sales, royalties and milestones reached £5.03m, including a £0.87m milestone payment.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 3 April 2023
Language
Pages
File size

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Report overview

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 3 April 2023
Language
Pages
File size

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Report and Financial Statements

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.

Report and Financial Statements

Report overview

Document

Standards & Assurance

ESG & Materiality

ESG data

Build your research dataset.